SCHEMBL5160415

SCHEMBL5160415

CC(C)(C)OC(=O)CC(=O)c1cn[nH]c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CCNB2 O95067 1/20 0.35
CCNE2 O96020 1/20 0.35
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCNB1 P14635 1/20 0.35
CCND1 P24385 1/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
ACACB O00763 3/20 0.34
NOS2 P35228 1/20 0.33
HTT P42858 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LATS1 O95835 1/20 0.32
PTPRC P08575 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160875 0.83 MEN1 (0.41) ALDH1A1KDM4EACACBNOS2HTT
SCHEMBL5162787 0.79 KMT2A (0.53) ALDH1A1KDM4EACACB
SCHEMBL16061725 0.78 CA12 (0.39) ALDH1A1NOS2HTTGPR119
SCHEMBL5158384 0.77 ACACB (0.41) ALDH1A1ACACBNOS2HTT
SCHEMBL5160500 0.77 HCAR2 (0.39) ALDH1A1KDM4ECCNB2CCNE2CDK1
Potassium SCHEMBL30423737 0.76 CA12 (0.38) ALDH1A1NOS2HTTGPR119
SCHEMBL20797184 0.75 ALDH1A1 (0.38) ALDH1A1KDM4EACACBNOS2HTT
SCHEMBL25475324 0.75 NAMPT (0.41) ALDH1A1ACACBHTT
SCHEMBL5161535 0.75 ALDH1A1 (0.39) ALDH1A1ACACBNOS2HTT
SCHEMBL5164288 0.74 SCN3A (0.36) ALDH1A1KDM4EACACBPTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ALDH1A1 273/4885KDM4E 862/4885CCNB2 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.